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Neuroﬁbromatosis type 1 (NF1; OMIM 162200) is an autosomal dominant disorder caused by a wide
variety of germline mutations in the NF1 gene. Nearly all individuals with NF1 exhibit café-au-lait
macules before the age of 2,1 but can also develop numerous other medical problems, including autism,
cognitive deﬁcits, tumors, and congenital heart defects. Although the clinical variability inherent in NF1
has been attributed to stochastic events, it is possible that the speciﬁc germline NF1 mutation might be
one factor underlying this heterogeneity. To illustrate this point, we report a family with 2 aﬀected
members harboring a missense mutation in the NF1 gene who lack the classic features of NF1.
The proband came to medical attention for failure to thrive, hypotonia, global delay, projectile
vomiting, and feeding problems, necessitating the placement of a gastrostomy tube at 9 months of age.
Although the pregnancy and vaginal delivery at 39 weeks of gestation were uncomplicated, soon after
birth, a patent foramen ovale and pulmonic valve stenosis were noted. Because her father had several
cutaneous masses, later pathologically determined to be lipomas, the patient underwent chromosomal
microarray (normal) and NF1 genetic testing, revealing a c.3445A>G (p.Met1149Val) germline
mutation in the NF1 gene, which was paternally inherited based on parental NF1 genetic testing. Her
father had no Lisch nodules, café-au-lait macules, or skinfold freckling. The patient also had no caféau-lait macules or skinfold freckling at 20 months of age, but had 2 mobile subcutaneous nodular
masses on her left chest, suggestive of neuroﬁbromas. No plexiform neuroﬁbromas were appreciated
on either the patient or her father, and no other members of their extended family had features of NF1.
The patient underwent brain and total spine neuroimaging, based on a left-hand preference, axial
hypotonia and a reluctance to bear weight on her legs, which were completely normal.
The ﬁnding of a germline NF1 mutation in this family raises several important points. First, this
missense mutation results in a methionine to valine change in an amino acid residue conserved in
vertebrates and ﬂies and predicted to be pathogenic using both PolyPhen (isoform-1, possibly_
damaging, 0.557; isoform-2, probably_damaging, 0.909) and SIFT (both isoforms, deleterious, 0)
variant pathogenicity analysis programs. Of interest, the mutated amino acid is 59 to the RAS GTPase
activating protein-related domain and is located within a segment involved in tubulin binding and
neuroﬁbromin homodimerization (residues 1,085–1,172).2 This variant has a frequency of 1 in
251,376 alleles in control individuals (0.000003978; gnomAD database). It has also been reported in
a 56-year-old woman with malignant melanoma whose tumor harbored both the Met1149Val
mutation and another NF1 mutation, creating a premature protein truncation (Leu1109X) within
the same domain and resulting in 5% of normal NF1 gene expression (cBioPortal).3 For these
reasons, it is highly likely that the Met1149Val mutation is pathogenic in this family.
Second, although this family did not have NF1, patients with NF1 and Met1149Val NF1 gene
mutations tend to exhibit a mild clinical phenotype, with a paucity of optic gliomas or plexiform
neuroﬁbromas.4 In contrast to the family reported herein, of the 48 patients with clinical assessments,4
94% had greater than 5 café-au-lait macules: Only 2 of these individuals had lipomas, and only 1 had
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pulmonic stenosis. The ﬁnding of this mutation in a family without
NF1 extends the spectrum of clinical manifestations that likely arise
from Met1149Val mutation.
Third, the lack of classic features of NF1 in these 2 individuals
add to the growing list of speciﬁc genotype-phenotype correlations in patients with NF1, including patients harboring Arg1809
missense and Met991 codon deletion mutations who do not
develop optic gliomas or neuroﬁbromas.4 Similarly, patients with
missense mutations located in residues spanning 844 to 848 have
been reported to exhibit more severe disease complications.5 As
the diﬀerential eﬀects of speciﬁc germline NF1 gene mutations
become elucidated, it is possible that they will help to deﬁne
speciﬁc contact points for neuroﬁbromin binding partners that
underlie these unique eﬀects.
Finally, previous work from our laboratory has shown that different germline NF1 gene mutations create dissimilar biological
eﬀects. Using human-induced pluripotent stem cells and mice
genetically engineered with NF1 patient NF1 gene mutations,
we found striking diﬀerences in neuronal diﬀerentiation6 and
optic glioma formation.7 Surprisingly, this variability was not the
result of diﬀerent levels of RAS hyperactivation, but rather
reﬂected other functions of neuroﬁbromin, some of which remain to be deﬁned. These observations suggest that other
readouts for neuroﬁbromin activity, besides RAS pathway signaling, are needed to characterize the contributions of diﬀerent
germline NF1 gene mutations to human disease pathobiology.
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